Growth • Incyte
INCY
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
14,5%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
-24,8%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-40,8%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-40,7%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
0%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-13,9%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!